Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation

Authors

Nicole P Daukshus, Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Anthony Cirincione, Department of Pharmacy, Maine Medical Center, Portland, Maine, USA.
Molly Siver, Department of Pharmacy, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Sherry Mathew, Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Binni Kunvarjee, Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Amelia Chan, Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Jaap Jan Boelens, Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Susan K. Seo, Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Genovefa A. Papanicolaou, Infectious Disease Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Nancy A. Kernan, Stem Cell Transplantation and Cellular Therapies, MSK Kids, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

Document Type

Article

Publication Date

7-21-2022

Institution/Department

Pharmacy

Journal Title

Journal of the Pediatric Infectious Diseases Society

MeSH Headings

Acetates; Adolescent; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections (drug therapy, prevention & control); Hematopoietic Stem Cell Transplantation (adverse effects); Humans; Quinazolines

Abstract

There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.

First Page

337

Last Page

340

Recommended Citation

P Daukshus N, Cirincione A, Siver M, et al. Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation. J Pediatric Infect Dis Soc. 2022;11(7):337-340. doi:10.1093/jpids/piac017